Published in Eur Urol on November 15, 2006
Meta-analysis of studies analyzing the role of human papillomavirus in the development of bladder carcinoma. Korean J Urol (2012) 1.35
99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: symbionts and immunopathology in chronic diseases: insights from evolution. Clin Exp Immunol (2010) 0.86
Detection of human papillomavirus infection and p16 immunohistochemistry expression in bladder cancer with squamous differentiation. PLoS One (2014) 0.79
Tumorgenesis due to papillomavirus infection was first demonstrated in rabbits and cattle early last century. Eur Urol (2007) 0.75
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Many sequence variants affecting diversity of adult human height. Nat Genet (2008) 12.80
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol (2006) 8.78
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet (2009) 6.91
Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet (2008) 6.69
Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med (2011) 6.34
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol (2011) 5.59
Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med (2008) 4.68
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet (2010) 3.93
DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res (2002) 3.78
Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol (2009) 3.69
DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol (2003) 3.52
Multiple-triazole-resistant aspergillosis. N Engl J Med (2007) 3.33
Stem cell characteristics in prostate cancer cell lines. Eur Urol (2009) 3.21
Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology (2011) 3.04
Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis (2009) 3.03
Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol (2009) 2.99
Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology (2011) 2.92
The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol (2009) 2.92
ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol (2009) 2.91
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol (2009) 2.88
Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis (2011) 2.84
Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med (2010) 2.83
Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol (2004) 2.82
MR-guided biopsy of the prostate: an overview of techniques and a systematic review. Eur Urol (2008) 2.77
MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol (2008) 2.76
Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet (2009) 2.76
Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat (2009) 2.63
Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res (2007) 2.63
A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet (2010) 2.56
Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology (2006) 2.49
Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol (2008) 2.48
Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging. Radiology (2012) 2.47
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45
A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet (2011) 2.43
Infection with multiple viruses is not associated with increased disease severity in children with bronchiolitis. Pediatr Pulmonol (2011) 2.32
Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol (2009) 2.31
Aspergillus PCR: one step closer to standardization. J Clin Microbiol (2010) 2.23
Saffold virus, a human Theiler's-like cardiovirus, is ubiquitous and causes infection early in life. PLoS Pathog (2009) 2.15
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol (2010) 2.13
Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology (2005) 2.10
Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis (2013) 2.09
Respiratory infections in Eñepa Amerindians are related to malnutrition and Streptococcus pneumoniae carriage. J Infect (2013) 2.06
A case of abiraterone acetate withdrawal. Eur Urol (2013) 2.06
Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the roche linear array HPV genotyping test. J Clin Microbiol (2006) 2.05
Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol (2010) 1.98
Urinary markers in bladder cancer. Eur Urol (2007) 1.95
Azole-resistant central nervous system aspergillosis. Clin Infect Dis (2009) 1.94
Prostate cancer: body-array versus endorectal coil MR imaging at 3 T--comparison of image quality, localization, and staging performance. Radiology (2007) 1.92
The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol (2011) 1.90
The clinical epidemiology of urachal carcinoma: results of a large, population based study. J Urol (2012) 1.88
The role of genetic markers in the management of prostate cancer. Eur Urol (2012) 1.88
A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol (2011) 1.84
Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology (2005) 1.82
Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol (2012) 1.81
Discovery of common variants associated with low TSH levels and thyroid cancer risk. Nat Genet (2012) 1.81
Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood (2011) 1.79
Percutaneous tibial nerve stimulation in the treatment of overactive bladder: urodynamic data. Neurourol Urodyn (2003) 1.78
A viral protein that blocks Arf1-mediated COP-I assembly by inhibiting the guanine nucleotide exchange factor GBF1. Dev Cell (2006) 1.77
Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS One (2010) 1.77
Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS One (2012) 1.71
Alcohol consumption and risk of prostate cancer in middle-aged men. Int J Cancer (2005) 1.69
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother (2009) 1.69
The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res (2007) 1.68
Cadherin-11 is expressed in detrusor smooth muscle cells and myofibroblasts of normal human bladder. Eur Urol (2007) 1.68
Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene (2004) 1.67
Posterior tibial nerve stimulation in the treatment of urge incontinence. Neurourol Urodyn (2003) 1.67
Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial. J Clin Oncol (2012) 1.66
Interlaboratory evaluation of different extraction and real-time PCR methods for detection of Coxiella burnetii DNA in serum. J Clin Microbiol (2010) 1.65
Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol (2003) 1.65
Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol (2011) 1.63
Discrepancy between clinical staging through bimanual palpation and pathological staging after cystectomy. Urol Oncol (2010) 1.63
Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol (2012) 1.63
Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology (2004) 1.62
The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival. Eur J Public Health (2010) 1.62
A proline-rich region in the coxsackievirus 3A protein is required for the protein to inhibit endoplasmic reticulum-to-golgi transport. J Virol (2005) 1.59
European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum Mol Genet (2011) 1.58
Single-nucleotide polymorphism in the E-cadherin gene promoter modifies the risk of prostate cancer. Int J Cancer (2002) 1.58
Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol (2006) 1.56
Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol (2009) 1.54
Ultrasound detection of rotator cuff tears: observer agreement related to increasing experience. AJR Am J Roentgenol (2010) 1.54
Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J Urol (2006) 1.51
Effects of picornavirus 3A Proteins on Protein Transport and GBF1-dependent COP-I recruitment. J Virol (2006) 1.50
Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate (2011) 1.49
Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. Eur Urol (2007) 1.49
Genotypic diversity of Coxiella burnetii in the 2007-2010 Q fever outbreak episodes in The Netherlands. J Clin Microbiol (2011) 1.49
Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother (2010) 1.49
Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother (2011) 1.49